SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending as investors discuss its potential inclusion in the S&P 500, with the official announcement expected soon. The community is weighing the potential for a short squeeze against the historical trend of stocks dropping after being added to the index. Optimistic traders believe the inclusion, along with upcoming events, will drive the stock higher.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its recent momentum and growing number of watchers, with many highlighting upcoming utilities. Community members are expressing bullish sentiment, anticipating further gains and airdrops for NFT holders. The conversation also reflects excitement around staking and the project's overall development.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as the community rallies around its unique rewards system, which distributes Solana ($SOL.X) directly to holders, regardless of price fluctuations. Recent discussions highlight the strength and resilience of the community, with many emphasizing that holding $IMG.X provides passive income superior to traditional investments, while also mentioning a new partnership with Kimbo Slice Jr.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as it joins the S&P 500, sparking excitement and debate about potential short squeezes and future price movement. The community is discussing whether the stock was pumped prior to the announcement and speculating on profit-taking strategies. Some investors express frustration for selling earlier, while others are optimistic about long-term growth.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Traders are focused on whether Strategy will be added to the S&P 500, with the announcement expected soon, while also tracking the company's significant bitcoin holdings as a potential driver. Community discussions revolve around the potential impact of S&P 500 inclusion and the correlation between the stock's performance and Bitcoin's price movements, as well as analyst sentiment. Some traders express concerns about possible manipulation and overinflated expectations, while others remain optimistic about the stock's prospects.

THE COQ FATHER BOSS

THE COQ FATHER BOSS ($BOSSCOQ.X) is trending as the community rallies around the newly launched meme coin, emphasizing holding and anticipating potential major exchange listings. The locked liquidity and Coinbase involvement claims are key talking points, with community members actively encouraging each other to accumulate and 'not sell their COQ'.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending due to discussions surrounding a report linking Tylenol use during pregnancy to autism, sparking community debate about the validity and potential market impact. Some investors view the dip as a buying opportunity, dismissing the report, while others express concern over potential lawsuits and long-term effects on the company. The broader context includes Kenvue's position as a consumer health company and its relationship with Johnson & Johnson.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to its low float, with traders speculating it could be the next stock to experience a significant squeeze. The community is actively discussing its potential for a rapid price increase, drawing comparisons to other low-float stocks that have recently made substantial moves. A recent land sale boosting NAV is also circulating.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending as investors discuss the potential impact of warrant conversions, with some expressing frustration over the company's language regarding possible acquisitions. The community is also weighing oversold signals, awaiting news catalysts, and debating the stock's short-term direction amid broader discussions about solid-state battery technology and market manipulation. Some traders express bullish sentiment while others remain skeptical, citing past performance and management decisions.

Peko is the perfect fusion between the panda, a beloved symbol in Chinese culture, and the Maneki-neko, the iconic Japanese lucky cat. This unique combination embodies prosperity, good fortune, and financial success for those who hold it.  With a distinctive collar inscribed with the name of Trump, currently the President of the United States, Peko symbolizes a message of support and optimism for the crypto world, connecting the international investment community with the belief in luck and financial opportunities.  Holding Peko means having more than just a memecoin — it’s a true digital amulet promising to attract fortune in every investment. Make Peko your partner for financial success!

PEKO

PEKO.X is trending as a "sleeper gem" with a strong community rallying behind it, anticipating a significant pump. Conversations highlight its potential for explosive growth, with many noting the "diamond hands" and "bags packed" in anticipation of a moonshot. The community is focused on its low-cap status and the potential for high returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%

The consensus price target hints at a 102.4% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 75.7% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Short sellers pulled back from Enliven Therapeutics last week, with Ortex data, compiled by The Fly,&nbsp; showing a sharp decline in short interest from 25.7% to 18.4% — the lowest since April 2023.&nbsp;The unwind coincided with a spike in trading volume, triggered by updated Phase 1 results for the company’s chronic myeloid leukemia (CML) candidate ELVN-001 and a bullish initiation from Goldman Sachs.Enliven Therapeutics shares closed at $21.3 on Friday, down 1.3% on the day.Ortex also reported that days to cover, a key metric representing the average number of days it would take shorts to cover their positions at current volume, dropped to 6.9 from 7.8, a nine-month low.&nbsp;The estimated short interest had ranged between 24% and 29% since October 2023.The catalyst was the company’s presentation at the European Hematology Association (EHA) Congress in Milan.&nbsp;Updated data from the ongoing Phase 1 ENABLE trial showed that 25 of 53 evaluable patients without the T315I mutation,&nbsp;or nearly 47%, achieved or maintained major molecular response (MMR) by week 24.&nbsp;The patients in the study were heavily pretreated, with 67% having received three or more prior TKIs.Enliven said ELVN-001 remained well-tolerated across all doses.&nbsp;The drug showed no signs of enhanced cardiovascular risk or arterial occlusive events, with just 3.4% of patients requiring dose reductions due to adverse events and 4.6% discontinuing due to side effects.&nbsp;The drug’s pharmacokinetics support once-daily oral dosing without fasting restrictions and minimal drug-drug interaction, which is a key benefit given&nbsp;that the average CML patient takes about five medications.Additionally, Goldman Sachs initiated coverage on Enliven Therapeutics with a ‘Buy’ rating and a $37 price target, citing positive Phase 1 data for ELVN-001 and plans to start a Phase 3 trial in 2026.&nbsp;The firm said the drug remains well-tolerated, with no added cardiovascular risk, and highlighted its once-daily dosing potential and minimal drug interaction profile.On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.The stock has declined 10.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’

Ortex data shows short interest in Enliven Therapeutics had hovered between 24% and 29% since October 2023.

Equity

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference PR Newswire BOULDER, Colo., Feb...

Mizuho refreshes its US top picks list for January

Investing.com --  Mizuho  (NYSE:MFG) has updated its US Top Picks list for January, adding Chewy (NYSE:CHWY), GE Vernova (NYSE:GEV), Enliven Therapeutics Inc (NASDAQ:ELVN), Quest Diagnostics (NYSE:DGX), DuPont de Nemours (NYSE:DD), and Salesforce (NYSE:CRM). These selections reflect Mizuho’s highest-conviction ideas driven by catalysts expected to play out over the next 12 months.

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update PR Newswire...

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference Enliven Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire BOULDER, Colo., Nov. 7, 2024...

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket PR Newswire VANCOUVER, BC, Oct. 4, 2024 USA News Group...

Enliven Therapeutics: A Strong Buy on Promising CML Treatments and Market Potential

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Enliven Therapeutics (ELVN Research Report). The associated price targ...

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday.
Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday's session.
read more...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

ELVN
Enliven Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ELVN News

ELVN Enliven Therapeutics Inc